<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H82CA2A3A3EEB4460B538B8646CD63EB0" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 4975 IH: SALTS Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-06-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4975</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140625">June 25, 2014</action-date>
			<action-desc><sponsor name-id="T000238">Mr. Thornberry</sponsor> (for himself and <cosponsor name-id="S000583">Mr. Smith of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act relating to controlled substance analogues.</official-title>
	</form>
	<legis-body id="HD26C5AC2630945A3A92DC1EBDC20BC5E" style="OLC">
		<section id="HBCE75F96A5FB4AA3AC482AA2FE5B8D48" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Synthetic Abuse and Labeling of Toxic Substances Act of 2014</short-title></quote> or the <quote>SALTS Act</quote>.</text>
		</section><section id="HC245649640464D47A823D84E4A77872A" section-type="subsequent-section"><enum>2.</enum><header>Controlled substance analogues</header><text display-inline="no-display-inline">Section 203 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/813">21 U.S.C. 813</external-xref>) is amended—</text>
			<paragraph id="H6326CFC45EEA4982BD7E2558D116AFE6"><enum>(1)</enum><text>by striking <quote>A controlled</quote> and inserting <quote>(a) <header-in-text level="subsection" style="OLC">In general</header-in-text>.—A controlled</quote>; and</text>
			</paragraph><paragraph id="HD234123DED814BD99953B6E75B771AF5"><enum>(2)</enum><text>by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HFA71FCB795E74648B6DB8CA14FCFA62A" style="OLC">
					<subsection id="H673882732B484FC6831E70699132B5DD"><enum>(b)</enum><header>Determination</header><text>In determining whether a controlled substance analogue was intended for human consumption under
			 subsection (a), the following factors may be considered, along with any
			 other relevant factors:</text>
						<paragraph id="H38E95640BD1845E7A77CD959A5BB5AE3"><enum>(1)</enum><text>The marketing, advertising, and labeling of the substance.</text>
						</paragraph><paragraph id="HCFCF86A3CFCB4725B433CC409E4BAAD3"><enum>(2)</enum><text>The known efficacy or usefulness of the substance for the marketed, advertised or labeled purpose.</text>
						</paragraph><paragraph id="H0A916056DE5544F99A1100B7832CFCE5"><enum>(3)</enum><text>The difference between the price at which the substance is sold and the price at which the
			 substance it is purported to be or advertised as is normally sold.</text>
						</paragraph><paragraph id="HDEE9D617AEA74FC6B5A25A932412763C"><enum>(4)</enum><text>The diversion of the substance from legitimate channels and the clandestine importation,
			 manufacture, or distribution of the substance.</text>
						</paragraph><paragraph id="HFD7146C5C8C148DABBE0E0B368AFA53B"><enum>(5)</enum><text>Whether the defendant knew or should have known the substance was intended to be consumed by
			 injection, inhalation, ingestion, or any other immediate means.</text>
						</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="HCFC86BAFFB564B9589B4D1AE654B6F29"><enum>(c)</enum><header>Limitation</header><text>For purposes of this section, evidence that a substance was not marketed, advertised, or labeled
			 for human consumption, by itself, shall not be sufficient to establish
			 that the substance was not intended for human consumption.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</paragraph></section></legis-body>
</bill>


